Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 23, 2024 11:52am
119 Views
Post# 36003374

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takes

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takesEveryone should vote how they feel is best but I think it might be worthwhile to think through the vote for Tea. She was placed on the board by IQ. IQ's interests at this point may or may not align with legacy shreholders and, to the extent they don't align, she will be voting for what IQ wants versus what might be best for legacy shareholders. Additionally, in the highly unlikely circumstance that legacy shareholders prevailed in this years vote and were able to replace all but Tea and Zwink, Tea would be part of the process of adding new members to the board and, again, who she would recommend to the new board might not be who legacy shareholders would want on the board. 

Again, most likely none of this actually matters since the institutional shareholders will probably vote in favor and the board the company has nominated will be elected. But on the off chance that does not occur, I would think it might be wise for those who choose to vote against the board to also vote against Tea. 

I do also think it might be smart to keep at least one of the old directors on the board for continuity's sake. Maybe Arena since if somehow TH-1902 suddenly becomes relevant agaain, his medical/regulatory expertise might be valuable? IF Zwick were left on his own, he might just resign rather than take on the job of trying to rebuild the board himself.

Just thinking out loud and am open to other's suggestions as to how we might vote our shares.

 
bull111 wrote: Voted 100k new shares for Tea & Zwick and agaist the rest.....my friends will vote the same way.
Enough is enough!!!


<< Previous
Bullboard Posts
Next >>